Journal
SIGNAL TRANSDUCTION AND TARGETED THERAPY
Volume 6, Issue 1, Pages -Publisher
SPRINGERNATURE
DOI: 10.1038/s41392-021-00484-9
Keywords
-
Categories
Funding
- National Science Fund for Distinguished Young Scholars [81625003]
- National Science and Technology Major Project [2017ZX10203205]
- National Science and Technology Key Program [81930016]
- Key R&D Project of Zhejiang Province [2019C03050]
- National Natural Science Foundation of China [81801824]
Ask authors/readers for more resources
Tumor-associated macrophages (TAMs) play a significant role in tumor immunotherapies, with potential therapeutic value in enhancing treatment outcomes.
The current treatment strategies in advanced malignancies remain limited. Notably, immunotherapies have raised hope for a successful control of these advanced diseases, but their therapeutic responses are suboptimal and vary considerably among individuals. Tumor-associated macrophages (TAMs) are a major component of the tumor microenvironment (TME) and are often correlated with poor prognosis and therapy resistance, including immunotherapies. Thus, a deeper understanding of the complex roles of TAMs in immunotherapy regulation could provide new insight into the TME. Furthermore, targeting of TAMs is an emerging field of interest due to the hope that these strategies will synergize with current immunotherapies. In this review, we summarize recent studies investigating the involvement of TAMs in immune checkpoint inhibition, tumor vaccines and adoptive cell transfer therapies, and discuss the therapeutic potential of targeting TAMs as an adjuvant therapy in tumor immunotherapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available